Drugs / ALN-CFB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07187401 | Feb 2026 → Nov 2029 expected | paroxysmal nocturnal hemoglobinuria | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALN-CFB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07187401 ↗ |
| Modality | Small interfering RNA (siRNA) | “ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B” NCT07187401 ↗ |
| Target | CFB | “ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B” NCT07187401 ↗ |